Kristine Romine Net Worth

The estimated Net Worth of Kristine Romine is at least $52.7 millier dollars as of 29 May 2019. Kristine Romine owns over 2,090 units of Evolus Inc stock worth over $52,682 and over the last 7 years Kristine sold EOLS stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Kristine Romine EOLS stock SEC Form 4 insiders trading

Kristine has made over 7 trades of the Evolus Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Kristine bought 2,090 units of EOLS stock worth $30,869 on 29 May 2019.

The largest trade Kristine's ever made was buying 40,562 units of Evolus Inc stock on 20 May 2019 worth over $780,819. On average, Kristine trades about 8,420 units every 36 days since 2018. As of 29 May 2019 Kristine still owns at least 3,450 units of Evolus Inc stock.

You can see the complete history of Kristine Romine stock trades at the bottom of the page.

What's Kristine Romine's mailing address?

Kristine's mailing address filed with the SEC is 520 Newport Center Dr #1200, Newport Beach, CA 92660, USA.

Insiders trading at Evolus Inc

Over the last 7 years, insiders at Evolus Inc have traded over $244,915,132 worth of Evolus Inc stock and bought 3,308,677 units worth $53,545,237 . The most active insiders traders include Biopharma, Inc. Aeon, Inc. Medytox et 1 Llc Alphaeon. On average, Evolus Inc executives and independent directors trade stock every 25 days with the average trade being worth of $3,606,270. The most recent stock trade was executed by Sandra Beaver on 6 September 2024, trading 3,276 units of EOLS stock currently worth $49,074.

What does Evolus Inc do?

evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.

Complete history of Kristine Romine stock trades at Evolus Inc

Evolus Inc executives and stock owners

Evolus Inc executives and other stock owners filed with the SEC include:

• Michael Jafar,
  Chief Commercial Officer
• David Moatazedi,
  President, Chief Executive Officer, Director
• Rui Avelar,
  Chief Medical Officer, Head of Research & Development
• David Moatazedi,
  Pres, CEO & Director
• Lauren Silvernail,
  Chief Financial Officer, Executive Vice President - Corporate Development
• Lauren P. Silvernail,
  CFO & Exec. VP of Corp. Devel.
• Dr. Rui Avelar Dip.SportMed, M.D., C.CFP,
  Chief Medical Officer and Head of R&D
• Karah Parschauer,
  Independent Director
• Peter Farrell,
  Independent Director
• Vikram Malik,
  Chairman of the Board
• David Gill,
  Independent Director
• Robert Hayman,
  Independent Director
• Simone Blank,
  Director
• Tram Bui,
  IR Contact Officer
• Jeff Plumer,
  General Counsel
• Jessica Novak,
  Sr. VP of HR
• Crystal Muilenburg,
  Chief Marketing Officer
• Kurt Knab,
  VP of Sales
• Jeffrey J. Plumer,
  Gen. Counsel
• David K. Erickson,
  VP of Investor Relations
• Biopharma, Inc. Aeon,
  
• Sandra Beaver,
  Chief Financial Officer
• Crystal Muilenburg,
  Chief Marketing Officer
• Albert G Iii White,
  Director
• Kristine Romine,
  Director
• Bosun Hau,
  Director
• 1 Llc Alphaeon,
  
• Brady Stewart,
  Director
• Tomoko Yamagishi Dressler,
  Chief Marketing Officer
• Inc. Medytox,